DERMATA THERAPEUTICS INC (DRMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.21-1.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DRMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
DRMA — earnings miss
Dated 2026-08-11
as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this
Why it matters: Lower losses show good cost control and better operations.
Supportive ifOperating losses decrease to less than -$1.93M in Q2 2026.
Worry ifOperating losses worsen or stay above -$1.93M in Q2 2026.
Why it matters: New product launches can drive revenue growth and expand the brand's market presence. This is crucial for Dermata's strategy.
Supportive ifDermata shares a timeline for the launch of its second DTC product. This comes after the Foundational Treatment.
Worry ifNo updates or delays for the second product. This may mean issues in development.
Why it matters: Cash levels are critical for funding operations. A drop could signal financial distress.
Worry ifCash reserves remain above $4 million as of Q4 2026.
Less concerning ifCash reserves fall below $4 million by Q4 2026.
Why it matters: Raising money is key for running the business. It shows the company is healthy.
Supportive ifThere is news of a new private placement or ATM offering over $500,000.
Worry ifNo news about raising money or a failed offering.
Why it matters: A clear timeline may show Dermata can grow its product line and make more money.
Watch forManagement shares a launch date for the second product.
Also watch forNo updates are provided on the second product's launch timeline.
Why it matters: Earnings results will show if the company is getting better at making money.
Watch forEarnings are better than expected. Revenue is up and losses are down.
Also watch forEarnings are below expectations. This shows ongoing money issues.
Why it matters: High cash burn could signal financial strain and impact future operations.
Worry ifCash burn in Q3 2026 is less than $3 million, indicating better cash management.
Less concerning ifCash burn is over $3 million. This raises worries about sustainability.
Why it matters: This launch marks Dermata's entry into the consumer skincare market. It is key for generating revenue.
Supportive ifThe product launches on August 25, 2026. It gets good feedback from consumers.
Worry ifThe launch is delayed or fails to generate initial sales.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,064 loss on $10,000 · 10.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,171 loss on $10,000 · 81.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.